Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33


Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.

Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ Jr, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X.

J Clin Oncol. 2017 May 11:JCO2016714758. doi: 10.1200/JCO.2016.71.4758. [Epub ahead of print]


ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology.

Antonia SJ, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE, Gerber DE, Juergens R, Shepherd F, Laurie SA, Young T, Geese WJ, Agrawal S, Li X, Hellmann MD.

J Thorac Oncol. 2016 Nov;11(11S):S250-S251. doi: 10.1016/j.jtho.2016.09.008. Epub 2016 Oct 28. No abstract available.


Patterns of Failure After Surgery for Non-Small-cell Lung Cancer Invading the Chest Wall.

Tandberg DJ, Kelsey CR, D'Amico TA, Crawford J, Chino JP, Tong BC, Ready NE, Wright A.

Clin Lung Cancer. 2016 Nov 21. pii: S1525-7304(16)30362-X. doi: 10.1016/j.cllc.2016.11.008. [Epub ahead of print]


Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ.

Lancet Oncol. 2017 Jan;18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6. Epub 2016 Dec 5.


Quantifying the Dynamics of Field Cancerization in Tobacco-Related Head and Neck Cancer: A Multiscale Modeling Approach.

Ryser MD, Lee WT, Ready NE, Leder KZ, Foo J.

Cancer Res. 2016 Dec 15;76(24):7078-7088. Epub 2016 Oct 20.


Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.

Boyer MJ, Gu L, Wang X, Kelsey CR, Yoo DS, Onaitis MW, Dunphy FR, Crawford J, Ready NE, Salama JK.

Lung Cancer. 2016 Aug;98:76-8. doi: 10.1016/j.lungcan.2016.05.014. Epub 2016 May 25.


Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?

Clarke JM, Wang X, Ready NE.

Transl Lung Cancer Res. 2015 Dec;4(6):804-8. doi: 10.3978/j.issn.2218-6751.2015.05.03.


Genetic variants in ABCG1 are associated with survival of nonsmall-cell lung cancer patients.

Wang Y, Liu H, Ready NE, Su L, Wei Y, Christiani DC, Wei Q.

Int J Cancer. 2016 Jun 1;138(11):2592-601. doi: 10.1002/ijc.29991. Epub 2016 Jan 30.


Adaptive planning using positron emission tomography for locally advanced lung cancer: A feasibility study.

Kelsey CR, Christensen JD, Chino JP, Adamson J, Ready NE, Perez BA.

Pract Radiat Oncol. 2016 Mar-Apr;6(2):96-104. doi: 10.1016/j.prro.2015.10.009. Epub 2015 Oct 23.


Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).

Salama JK, Gu L, Wang X, Pang HH, Bogart JA, Crawford J, Schild SE, Vokes EE, Ready NE.

J Thorac Oncol. 2016 Mar;11(3):361-9. doi: 10.1016/j.jtho.2015.11.001. Epub 2015 Dec 24.


Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.

Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM; TRILOGY ACS Investigators..

Eur Heart J. 2016 Jan 21;37(4):412-22. doi: 10.1093/eurheartj/ehv611. Epub 2015 Dec 5.


Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer.

Kelsey CR, Das S, Gu L, Dunphy FR 3rd, Ready NE, Marks LB.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):997-1004. doi: 10.1016/j.ijrobp.2015.09.007. Epub 2015 Sep 15.


Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR.

N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.


Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).

Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE.

J Clin Oncol. 2015 May 20;33(15):1660-5. doi: 10.1200/JCO.2014.57.3105. Epub 2015 Mar 2.


Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy.

Pepek JM, Marks LB, Berry MF, Ready NE, Gee NG, Coleman RE, D'Amico TA, Crawford J, Kelsey CR.

Pract Radiat Oncol. 2015 Mar-Apr;5(2):79-84. doi: 10.1016/j.prro.2014.05.002. Epub 2014 Jun 14.


Smoking history predicts for increased risk of second primary lung cancer: a comprehensive analysis.

Boyle JM, Tandberg DJ, Chino JP, D'Amico TA, Ready NE, Kelsey CR.

Cancer. 2015 Feb 15;121(4):598-604. doi: 10.1002/cncr.29095. Epub 2014 Oct 3.


Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer.

Denehy L, Hornsby WE, Herndon JE 2nd, Thomas S, Ready NE, Granger CL, Valera L, Kenjale AA, Eves ND, Jones LW.

J Thorac Oncol. 2013 Dec;8(12):1545-50. doi: 10.1097/JTO.0000000000000032.


Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?

Tandberg DJ, Gee NG, Chino JP, D'Amico TA, Ready NE, Coleman RE, Kelsey CR.

J Thorac Cardiovasc Surg. 2013 Oct;146(4):796-801. doi: 10.1016/j.jtcvs.2013.05.027. Epub 2013 Jul 16.


Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators..

N Engl J Med. 2012 Oct 4;367(14):1297-309. doi: 10.1056/NEJMoa1205512. Epub 2012 Aug 25.


A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

Vlahovic G, Meadows KL, Uronis HE, Morse MA, Blobe GC, Riedel RF, Zafar SY, Alvarez-Secord A, Gockerman J, Starodub AN, Ready NE, Anderson EL, Bendell JC, Hurwitz HI.

Cancer Chemother Pharmacol. 2012 Jul;70(1):95-102. doi: 10.1007/s00280-012-1889-8. Epub 2012 May 26.

Supplemental Content

Loading ...
Support Center